Cencora, Inc. $COR Shares Sold by Atle Fund Management AB

Atle Fund Management AB lowered its position in shares of Cencora, Inc. (NYSE:COR) by 9.1% in the third quarter, HoldingsChannel reports. The fund owned 28,608 shares of the company’s stock after selling 2,858 shares during the period. Cencora accounts for approximately 3.5% of Atle Fund Management AB’s investment portfolio, making the stock its 8th largest holding. Atle Fund Management AB’s holdings in Cencora were worth $8,941,000 as of its most recent SEC filing.

Several other hedge funds have also added to or reduced their stakes in COR. Cornerstone Wealth Group LLC raised its holdings in Cencora by 1.3% during the 3rd quarter. Cornerstone Wealth Group LLC now owns 2,383 shares of the company’s stock worth $745,000 after purchasing an additional 30 shares during the last quarter. Security Financial Services INC. raised its stake in shares of Cencora by 2.6% during the third quarter. Security Financial Services INC. now owns 1,325 shares of the company’s stock worth $414,000 after buying an additional 33 shares during the last quarter. Atlantic Edge Private Wealth Management LLC lifted its holdings in Cencora by 70.0% in the second quarter. Atlantic Edge Private Wealth Management LLC now owns 85 shares of the company’s stock valued at $25,000 after buying an additional 35 shares during the period. Hemington Wealth Management boosted its stake in Cencora by 12.0% in the third quarter. Hemington Wealth Management now owns 327 shares of the company’s stock valued at $102,000 after acquiring an additional 35 shares during the last quarter. Finally, Quadcap Wealth Management LLC grew its holdings in Cencora by 1.5% during the 2nd quarter. Quadcap Wealth Management LLC now owns 2,409 shares of the company’s stock worth $722,000 after acquiring an additional 36 shares during the period. Institutional investors own 97.52% of the company’s stock.

Cencora Price Performance

NYSE COR opened at $359.14 on Friday. The company has a debt-to-equity ratio of 4.32, a quick ratio of 0.55 and a current ratio of 0.90. The stock has a market cap of $69.67 billion, a price-to-earnings ratio of 45.17, a PEG ratio of 1.68 and a beta of 0.66. The business has a 50 day simple moving average of $347.62 and a 200 day simple moving average of $324.08. Cencora, Inc. has a 52-week low of $237.71 and a 52-week high of $377.54.

Cencora (NYSE:COR) last released its quarterly earnings results on Wednesday, November 5th. The company reported $3.84 earnings per share for the quarter, beating the consensus estimate of $3.79 by $0.05. Cencora had a net margin of 0.48% and a return on equity of 227.15%. The company had revenue of $83.73 billion during the quarter, compared to analysts’ expectations of $83.36 billion. During the same quarter in the prior year, the company earned $3.34 earnings per share. The business’s quarterly revenue was up 5.9% compared to the same quarter last year. Cencora has set its FY 2026 guidance at 17.450-17.75 EPS. Analysts anticipate that Cencora, Inc. will post 15.37 earnings per share for the current fiscal year.

Cencora Increases Dividend

The company also recently announced a quarterly dividend, which was paid on Monday, December 1st. Shareholders of record on Friday, November 14th were issued a dividend of $0.60 per share. This is a boost from Cencora’s previous quarterly dividend of $0.55. The ex-dividend date was Friday, November 14th. This represents a $2.40 dividend on an annualized basis and a yield of 0.7%. Cencora’s dividend payout ratio is currently 30.19%.

Insider Buying and Selling at Cencora

In related news, CEO Robert P. Mauch sold 5,096 shares of the stock in a transaction dated Tuesday, January 20th. The stock was sold at an average price of $354.73, for a total transaction of $1,807,704.08. Following the completion of the transaction, the chief executive officer directly owned 66,726 shares in the company, valued at approximately $23,669,713.98. This trade represents a 7.10% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, EVP Silvana Battaglia sold 1,677 shares of Cencora stock in a transaction that occurred on Friday, December 19th. The shares were sold at an average price of $345.00, for a total value of $578,565.00. Following the completion of the sale, the executive vice president directly owned 18,796 shares in the company, valued at approximately $6,484,620. This represents a 8.19% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Insiders have sold 20,316 shares of company stock valued at $7,151,265 in the last 90 days. 0.38% of the stock is currently owned by company insiders.

Wall Street Analysts Forecast Growth

A number of research firms have recently weighed in on COR. Jefferies Financial Group raised Cencora from an “underperform” rating to a “buy” rating in a research note on Thursday, January 22nd. Wall Street Zen lowered Cencora from a “buy” rating to a “hold” rating in a research note on Friday, November 28th. TD Cowen boosted their target price on Cencora from $350.00 to $400.00 and gave the stock a “buy” rating in a research report on Monday, November 10th. Weiss Ratings reaffirmed a “hold (c+)” rating on shares of Cencora in a research note on Monday, December 29th. Finally, Wells Fargo & Company lifted their price objective on shares of Cencora from $354.00 to $405.00 and gave the stock an “overweight” rating in a research note on Tuesday, November 11th. One research analyst has rated the stock with a Strong Buy rating, nine have issued a Buy rating and three have assigned a Hold rating to the stock. Based on data from MarketBeat, Cencora currently has a consensus rating of “Moderate Buy” and an average price target of $393.08.

Cencora Company Profile

Cencora (NYSE:COR) is a global healthcare services and pharmaceutical distribution company that provides end-to-end solutions across the pharmaceutical supply chain. The company’s core activities include wholesale drug distribution, specialty drug distribution, and the operation of specialty pharmacies, complemented by logistics, cold-chain management and other fulfillment services designed to support complex and temperature-sensitive therapies.

Beyond physical distribution, Cencora offers a range of commercial and patient-focused services for pharmaceutical manufacturers and healthcare providers.